NCT06164769 Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery
| NCT ID | NCT06164769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang University |
| Condition | Tumor of Pancreas |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2023-03-01 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic enucleation could preserve more healthy pancreatic tissues and functions with a low recurrence risk. However, conventional enucleation can cause significant intraoperative bleeding, especially in which tumors in the pancreatic head, neck, and uncinate process of pancreas, as these tissues are rich in blood supply, mainly including the abdominal trunk and the superior mesenteric artery. In this study, we developed a novel method to control the pancreatic blood flow in laparoscopic enucleation--blocking the abdominal trunk and superior mesenteric artery with vascular occlusion clips in the process of resection, and evaluated its effectiveness and safety.
Eligibility Criteria
Inclusion Criteria: * Benign or borderline tumors diagnosed pathologically, such as pancreatic neuroendocrine tumors, solid pseudopapillary tumors, and cystadenomas, without vascular invasion or distant metastasis * Tumors sited in the pancreatic head, neck, and uncinate process of pancreas * Blockade of both the abdominal trunk and superior mesenteric artery in the laparoscopic enucleation Exclusion Criteria: * Highly malignant pancreatic tumors, or tumors with infiltration or metastasis * Tumors of the body and tail of the pancreas * Transfer to LPD or laparotomy
Contact & Investigator
Bo Zhou, Dr.
PRINCIPAL INVESTIGATOR
The Second Affiliated Hospital, Zhejiang Chinese Medical University
Frequently Asked Questions
Who can join the NCT06164769 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 70 Years, studying Tumor of Pancreas. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06164769 currently recruiting?
Yes, NCT06164769 is actively recruiting participants. Contact the research team at shengyan@zju.edu.cn for enrollment information.
Where is the NCT06164769 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06164769 clinical trial?
NCT06164769 is sponsored by Zhejiang University. The principal investigator is Bo Zhou, Dr. at The Second Affiliated Hospital, Zhejiang Chinese Medical University. The trial plans to enroll 30 participants.